芳香性L-氨基酸脱碳酶缺乏症的基因疗法:安全应用和知识生成后续监测的要求
Agathe Roubertie1, Thomas Opladen2, Heiko Brennenstuhl2,3
1CHU Montpellier, Département de Neuropédiatrie, INM, Univ Montpellier, INSERM U 1298, Montpellier, France.
Journal of inherited metabolic disease
|July 4, 2023
概括
一种新的基因疗法,Eladocagene exuparvovec,为芳香L-氨基酸脱碳酶缺乏症 (AADCD) 提供因果治疗,这是一种严重的神经疾病. 为其质量保证的应用和患者管理制定了指导方针.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 芳香性L-氨基酸脱碳酶 (AADC) 缺乏症是一种严重的,早期发作的神经系统疾病,由多巴胺,血清素和甲基醇胺的综合缺乏引起.
- 针对AADC缺乏症的常规治疗有效性有限,特别是在严重的病例中.
研究的目的:
- 建立对接受基因治疗的AADC缺乏症患者的准备,管理和随访的要求和建议.
- 概述AADC缺陷基因疗法的质量保证应用的框架,包括Eladocagene exuparvovec.
主要方法:
- 国际神经递质相关疾病工作组 (iNTD) 使用了标准化的Delphi方法.
- 为AADC缺陷基因治疗方案制定结构性要求和建议.
主要成果:
- 以AAV2为基础的基因疗法Eladocagene exuparvovec针对皮,已在欧洲和英国获得批准.
- 这种基因疗法代表了一种因果治疗,为AADC缺乏症开启了一个新的治疗时代.
- 专业中心内的多学科团队方法是全面的病人护理所需的.
结论:
- 质量保证的基因疗法应用框架对于AADC缺陷至关重要.
- 由于长期结果数据有限,需要在独立注册表中进行结构化的后续跟踪和系统的数据收集.
相关概念视频
Gene Therapy
25.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.6K
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
298
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
298
Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220


